拜耳和Vividion Therapeutics将在2025年AACR年会上展示其不断发展的肿瘤学产品组合-动脉网

Bayer and Vividion Therapeutics to highlight advancing oncology portfolio at AACR 2025 Annual Meeting

拜耳等信源发布 2025-04-22 16:01



可切换为仅中文







April

四月

2025

10:00 AM

上午10:00

Europe/Amsterdam

欧洲/阿姆斯特丹

Bayer and Vividion Therapeutics to highlight advancing oncology portfolio at AACR 2025 Annual Meeting

拜耳和Vividion Therapeutics将在2025年AACR年会上展示其不断发展的肿瘤学产品组合。

Not intended for U.S. and UK Media – In the field of precision oncology:

不适用于美国和英国媒体——在精准肿瘤学领域：

Summary

摘要

In “New Drugs on the Horizon” session, Bayer will present preclinical data and results from clinical imaging on its investigational targeted alpha radiopharmaceutical being developed to treat tumors expressing Glypican-3 (GPC3) in patients with advanced hepatocellular carcinoma (HCC) / Preclinical data to be presented on the HER2/mEGFR inhibitor sevabertinib (BAY 2927088), an investigational agent developed for patients with non-small cell lung cancer (NSCLC) and other solid tumors with HER2 activating mutations / Preclinical data to be presented on investigational SOS1 inhibitor targeting KRAS dependent advanced solid tumors, such as NSCLC, pancreatic cancer and colorectal cancer / Translational pharmacokinetic-pharmacodynamic (PK/PD) model framework and preclinical data to be presented on selective, allosteric CyclinE1/CDK2 inhibitors, for treatment of CyclinE1 amplified tumors / Vividion Therapeutics will present preclinical data of its innovative Kelch-like ECH-associated protein 1 (KEAP1) activator, VVD-037, being developed to inhibit tumor growth and overcome resistance by allosterically promoting NRF2 degradation / Presentations reinforce Bayer’s commitment to develop new medicines that help improve and extend the lives of people living with cancer.

在“新药前沿”会议环节，拜耳公司将展示其研究中的靶向α放射性药物的临床前数据和临床影像结果，该药物正在开发用于治疗表达磷脂酰肌醇蛋白聚糖-3（GPC3）的晚期肝细胞癌（HCC）患者肿瘤 / 将展示HER2/mEGFR抑制剂sevabertinib（BAY 2927088）的临床前数据，这是一种为携带HER2激活突变的非小细胞肺癌（NSCLC）及其他实体瘤患者开发的研究性药物 / 将展示针对KRAS依赖型晚期实体瘤（如非小细胞肺癌、胰腺癌及结直肠癌）的研究性SOS1抑制剂的临床前数据 / 将展示选择性、变构CyclinE1/CDK2抑制剂的转化药代动力学-药效学（PK/PD）模型框架及临床前数据，用于治疗CyclinE1扩增的肿瘤 / Vividion Therapeutics将展示其创新Kelch样ECH相关蛋白1（KEAP1）激活剂VVD-037的临床前数据，该药物通过变构促进NRF2降解来抑制肿瘤生长并克服耐药性 / 这些报告进一步彰显了拜耳致力于开发帮助改善和延长癌症患者生命的新药。

Abstracts: ND09; 4348; 4349; 4373; 5610

摘要：ND09；4348；4349；4373；5610

Berlin, Germany, and Chicago (IL), USA, April 22, 2025

德国柏林，美国伊利诺伊州芝加哥，2025年4月22日

– Bayer and Vividion Therapeutics, Inc. (Vividion) will present the latest research on their advancing oncology portfolio at the upcoming

– 拜耳和维维迪恩治疗公司（Vividion Therapeutics, Inc.）将在即将举行的会议上展示他们不断发展的肿瘤学组合的最新研究成果。

American Association for Cancer Research (AACR) 2025 Annual Meeting

美国癌症研究协会（AACR）2025年年会

, taking place from April 25-30, 2025, in Chicago, USA. Bayer will present preclinical data as well as clinical imaging results from its evolving portfolio of targeted alpha therapy, an emerging class of targeted radionuclide therapy and a focus of Bayer’s precision drug development strategy in oncology.

，将于2025年4月25日至30日在美国芝加哥举行。拜耳将展示其不断发展的靶向α疗法组合的临床前数据及临床影像结果，靶向α疗法是一类新兴的靶向放射性核素疗法，也是拜耳在肿瘤学领域精准药物开发战略的重点。

In addition, the company will showcase encouraging preclinical and clinical research data on several compounds targeting intracellular tumor signaling pathways responsible for the development and survival of cancer, potentially offering new treatment opportunities in indications of high medical relevance.

此外，该公司还将展示几种针对细胞内肿瘤信号通路的化合物令人鼓舞的临床前和临床研究数据，这些信号通路负责癌症的发展和存活，可能为高医学相关性的适应症提供新的治疗机会。

Vividion, a wholly owned and independently operating subsidiary of Bayer AG, will provide insights into the development and characterization of its highly selective small molecule KEAP1 activator, being evaluated as a new therapeutic means of blocking the oncogenic pathways..

拜耳集团全资独立运营的子公司 Vividion 将介绍其高选择性小分子 KEAP1 激动剂的开发与特性研究，该激动剂正被评估作为一种阻断致癌通路的全新治疗手段。

During the “New Drugs on the Horizon” session, Bayer will introduce its

在“新药前沿”会议期间，拜耳将介绍其

investigational targeted alpha radiopharmaceutical

研究性靶向α放射性药物

(BAY 3547926) being developed to treat tumors expressing Glypican-3 (GPC3) in patients with advanced

（BAY 3547926）正在开发用于治疗表达磷脂酰肌醇蛋白聚糖-3（GPC3）的肿瘤，针对晚期患者。

hepatocellular carcinoma (HCC)

肝细胞癌 (HCC)

. GPC3 is an oncofetal protein overexpressed in 70-75 percent of HCC lesions which makes it an attractive target for targeted radionuclide therapy.

GPC3是一种在70%-75%的肝细胞癌（HCC）病灶中过度表达的胎瘤蛋白，这使其成为靶向放射性核素治疗的一个有吸引力的靶点。

1,2

This investigational radiotherapeutic delivers a highly potent alpha-particles to the GPC3-expressing cancer cells, aiming to induce DNA double-strand breaks and reduce cancer cell viability, which may potentially cause anti-tumor activity. The data presented will include preclinical

这种研究性的放射治疗药物将高活性的α粒子递送到表达GPC3的癌细胞，旨在诱导DNA双链断裂并降低癌细胞活力，这可能会引发抗肿瘤活性。所展示的数据将包括临床前数据。

in vitro

体外

and

和

in vivo

体内

characterization, along with the results of a clinical imaging study in patients with advanced HCC.

表现特征，以及在晚期肝细胞癌患者中进行的临床影像学研究结果。

From its focus area Precision Molecular Oncology, Bayer will present latest research on a novel targeted treatment option for patients with advanced

拜耳公司将从其重点领域精准分子肿瘤学出发，展示针对晚期患者的新型靶向治疗选择的最新研究。

non-small cell lung cancer

非小细胞肺癌

(NSCLC) harboring

（非小细胞肺癌）携带

HER2-activating mutations

HER2激活突变

. Derived from its strategic research alliance with the Broad Institute of MIT and Harvard, the investigational

源于其与麻省理工学院和哈佛大学布罗德研究所的战略研究联盟，该研究性

HER2/mEGFR inhibitor

HER2/mEGFR抑制剂

sevabertinib (BAY 2927088) is the first oral, reversible small molecule targeting human epidermal growth factor receptor 2 (HER2). The ongoing Phase I/II SOHO-01 study is evaluating its safety and efficacy. Its potential is underscored by Breakthrough Therapy Designations from both the US FDA and Chinese Centre for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).

sevabertinib（BAY 2927088）是首个口服、可逆的小分子，靶向人类表皮生长因子受体2（HER2）。正在进行的I/II期SOHO-01研究正在评估其安全性和有效性。其潜力得到了美国FDA和中国国家药品监督管理局（NMPA）药品审评中心（CDE）授予的突破性疗法认定的强调。

Beyond the SOHO-01 trial, sevabertinib (BAY 2927088) is also being assessed for its potential as a first-line therapy in patients with advanced non-small cell lung cancer (NSCLC), whose tumors have activating HER2 mutations in the Phase III SOHO-02 trial..

除了SOHO-01试验外，塞瓦伯替尼（BAY 2927088）还在III期SOHO-02试验中评估其作为一线疗法的潜力，用于治疗肿瘤携带激活HER2突变的晚期非小细胞肺癌（NSCLC）患者。

Bayer will provide insights into the discovery and characterization of its investigational oral selective

拜耳将提供对其研究中的口服选择性药物的发现和特性描述的见解

Son of Sevenless Homologue 1 (SOS1)

七无子同源物1（SOS1）

inhibitor BAY 3498264

抑制剂 BAY 3498264

，

which is currently being evaluated in a Phase I clinical trial in patients with

目前正在进行一期临床试验评估，针对患者

advanced KRAS-mutated tumors

先进的KRAS突变肿瘤

, such as non-small cell lung cancer (NSCLC), pancreatic cancer and colorectal cancer. This innovative clinical candidate with promising therapeutic potential across several tumor types, addresses the unmet medical need of improving efficacy of treatment targeting the mitogen-activated protein kinase (MAPK) signaling pathway which regulates cell proliferation and plays a critical role in tumor growth and carcinogenesis..

，如非小细胞肺癌（NSCLC）、胰腺癌和结直肠癌。这一具有前景的创新临床候选药物在多种肿瘤类型中展现出良好的治疗潜力，满足了提升针对调控细胞增殖、在肿瘤生长和癌变过程中起关键作用的丝裂原活化蛋白激酶（MAPK）信号通路治疗效果的未满足医疗需求。

Another abstract will present a translational pharmacokinetic-pharmacodynamic (PK/PD) modeling framework of novel, highly selective, next-generation

另一个摘要将介绍一种新型、高选择性、下一代的转化药代动力学-药效学（PK/PD）建模框架。

allosteric cyclin-dependent kinase 2 (CDK2) inhibitors

变构细胞周期蛋白依赖性激酶2（CDK2）抑制剂

. The amplification and overexpression of the CDK2 binding partner Cyclin E1 (CCNE1) is a key mechanism in various cancers, and selective CDK2/CCNE1 inhibition potentially offers a promising treatment for patients with CCNE1 overexpressing tumors. The use of state-of-the-art PKPD models is a valuable method for integrating multi-scale data to investigate the causal chain between dose and response.

细胞周期蛋白E1（CCNE1）作为CDK2结合伴侣的扩增和过表达是多种癌症中的关键机制，选择性抑制CDK2/CCNE1可能为CCNE1过表达肿瘤患者提供一种有前景的治疗方法。利用最先进的PKPD模型是一种有价值的方法，可以整合多尺度数据以研究剂量与反应之间的因果链。

Consequently, the development of a model framework based on preclinical .

因此，基于临床前的模型框架的开发。

in vitro

体外

and

和

in vivo

体内

data is of significant interest for the support of preclinical and clinical phases. Model evaluation and refinements based on clinical data will be key for further use during clinical development.

数据对于支持临床前和临床阶段具有重要意义。基于临床数据的模型评估和改进将是临床开发过程中进一步应用的关键。

Vividion will be presenting a poster outlining translational pharmacokinetic / pharmacodynamic (PK/PD) modeling for its innovative covalent small molecule

Vividion 将展示一张海报，概述其创新共价小分子的转化药代动力学/药效学 (PK/PD) 建模。

Kelch-like ECH-associated protein 1 (KEAP1) activator, VVD-037

Kelch样ECH相关蛋白1（KEAP1）激活剂，VVD-037

. KEAP1 is an E3 ligase that degrades NRF2, a master regulatory transcription factor that coordinates antioxidant, detoxification, and cytoprotective gene programs. NRF2 pathway hyper activation promotes malignant tumor growth and resistance to many standard-of-care therapies and is frequently detected in solid cancers such as non-small cell lung cancer, esophageal squamous cell carcinoma, and head and neck squamous cell carcinoma.

KEAP1是一种E3连接酶，可降解NRF2，NRF2是一个主导调控转录因子，协调抗氧化、解毒和细胞保护基因程序。NRF2通路的过度激活促进恶性肿瘤生长，并对许多标准治疗产生抗性，常在非小细胞肺癌、食管鳞状细胞癌和头颈部鳞状细胞癌等实体瘤中被检测到。

VVD-037 is being evaluated in a Phase I clinical trial as a single agent and in combination..

VVD-037 正在一项 I 期临床试验中作为单一药物及联合疗法进行评估。

Information on the registration as well as the virtual scientific program can be found

注册信息以及虚拟科学计划可以在以下位置找到

here

这里

。

Key presentations on Bayer and Vividion research to be presented at AACR 2025 are listed below.

以下是将在AACR 2025上展示的关于拜耳和Vividion研究的主要报告列表。

Oral presentation

口头报告

：

BAY 3547926: Novel targeted radionuclide therapy for hepatocellular carcinoma

BAY 3547926：新型靶向放射性核素治疗肝细胞癌

o Abstract ND09, Session: DDT03 – New Drugs on the Horizon: Part 3

摘要 ND09，会议：DDT03 – 新药前沿：第三部分

o Monday, April 28, 10:15 AM – 11:45 AM (AM), Room S406 (Vista Ballroom) – McCormick Place South (Level 4), Convention Center

o 星期一，4月28日，上午10:15 - 上午11:45，S406房间（Vista宴会厅）– 麦考密克会展中心南楼（4楼），会议中心

Poster presentations

海报展示

：

A translational pharmacokinetic-pharmacodynamic (PKPD) modeling framework of novel, highly selective, next-generation allosteric cyclin-dependent kinase 2 (CDK2) inhibitors

新型、高选择性、下一代变构细胞周期蛋白依赖性激酶2（CDK2）抑制剂的转化药代动力学-药效学（PKPD）建模框架

o Abstract #4348 / Session: Experimental and Molecular Therapeutics / Pharmacokinetics and Pharmacodynamics of Cancer Therapeutics

摘要 #4348 / 会议：实验与分子治疗学 / 癌症治疗药物的药代动力学与药效学

o Tuesday, April 29, 9:00 AM – 12:00 PM (PT), Section 20, Poster #13, Convention Center

o 星期二，4月29日，上午9:00 – 上午12:00（太平洋时间），第20节，海报#13，会议中心

Translational pharmacokinetic/pharmacodynamic (PK/PD) modeling for VVD-130037, an innovative covalent small molecule Kelch-like ECH-associated protein 1 (KEAP1) activator

VVD-130037 的转化药代动力学/药效学 (PK/PD) 建模，一种创新的共价小分子 Kelch 样ECH 相关蛋白 1 (KEAP1) 激活剂

o Abstract #4349 / Session: Experimental and Molecular Therapeutics / Pharmacokinetics and Pharmacodynamics of Cancer Therapeutics

摘要 #4349 / 会议：实验与分子治疗学 / 癌症治疗药物的药代动力学与药效学

o Tuesday, April 29

o 4月29日，星期二

，

9:00 AM - 12:00 PM, Section 20, Poster #14, Convention Center

上午9:00 - 上午12:00，第20区，海报#14，会议中心

Discovery and characterization of BAY 3498264: a small molecule inhibitor targeting the RAS-SOS1 interaction

发现并表征BAY 3498264：一种靶向RAS-SOS1相互作用的小分子抑制剂

o Abstract #4373 / Session: Experimental and Molecular Therapeutics / RAS Inhibitors

摘要 #4373 / 会议：实验与分子治疗学 / RAS抑制剂

o Tuesday, April 29, 9:00 AM – 12:00 PM (PT), Section 21, Poster #8, Convention Center

星期二，4月29日，上午9:00 – 上午12:00（太平洋时间），第21节，海报#8，会议中心

BAY 2927088: a novel treatment option for patients with NSCLC with HER2 mutations

BAY 2927088：一种针对HER2突变型非小细胞肺癌（NSCLC）患者的新治疗选择

o Abstract #5610 / Session: Experimental and Molecular Therapeutics / Kinase and Phosphatase Inhibitors 3

摘要 #5610 / 会议：实验与分子治疗学 / 激酶和磷酸酶抑制剂 3

o Tuesday, April 29, 2:00 PM – 5:00 PM (PT), Section 20, Poster #20, Convention Center

4月29日星期二，下午2:00 - 下午5:00（太平洋时间），第20区，海报#20，会议中心

About Oncology at Bayer

拜耳肿瘤学相关

Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The company has the passion and determination to develop new medicines that help improve and extend the lives of people living with cancer. The oncology franchise at Bayer includes several marketed products across diverse indications and multiple compounds in different stages of clinical development.

拜耳致力于通过推进一系列创新治疗方案来为更美好的生活提供科学支持。公司充满热情和决心，开发有助于改善和延长癌症患者生命的新药。拜耳的肿瘤学产品组合包括多种已上市的产品，涵盖不同的适应症，同时还有多个化合物处于临床开发的不同阶段。

We have a wealth of expertise in areas including Tumor Cell Intrinsic Pathways, Targeted Radionuclide Therapies, and selective Next-Generation Immuno-Oncology. With our portfolio we are advancing cancer treatments from early to metastatic stage, with the goal of extending survival while limiting side effects for the cancer patients we serve..

我们在肿瘤细胞内在通路、靶向放射性核素治疗和选择性下一代免疫肿瘤学等领域拥有丰富的专业知识。通过我们的产品组合，我们正在推进从早期到转移阶段的癌症治疗，目标是延长患者的生存期，同时减少副作用。

About Bayer

关于拜耳

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population.

拜耳是一家在医疗保健和营养等生命科学领域具有核心竞争力的全球性企业。秉承“人人健康，无饥饿”的使命，公司通过支持应对不断增长和老龄化的全球人口所带来的重大挑战，设计其产品和服务以帮助人类和地球繁荣发展。

Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros.

拜耳致力于通过其业务推动可持续发展并产生积极影响。同时，集团旨在通过创新和增长提高盈利能力并创造价值。拜耳品牌在全球范围内代表信任、可靠性和质量。在2024财年，该集团拥有约93,000名员工，销售额达466亿欧元。

R&D expenses amounted to 6.2 billion euros. For more information, go to .

研发费用达62亿欧元。欲了解更多信息，请访问。

www.bayer.com

。

About Vividion Therapeutics

关于Vividion Therapeutics

Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG, is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders. The company’s platform has enabled it to identify hundreds of previously unknown functional pockets on well-validated protein targets implicated in a wide range of diseases, while simultaneously identifying compounds from its proprietary covalent chemistry library that interact in a highly selective manner with those pockets.

Vividion Therapeutics, Inc. 是拜耳集团旗下的全资子公司，独立运营，是一家生物制药公司，利用新颖的发现技术，针对高价值、传统上无法成药的靶点，开发精准治疗药物以应对毁灭性癌症和免疫疾病。该公司平台使其能够识别出数百个先前未知的功能口袋，这些功能口袋位于与多种疾病相关、经过充分验证的蛋白质靶点上，同时从其专有的共价化学库中筛选出能以高度选择性方式与这些口袋相互作用的化合物。

The company is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high value, traditionally undruggable targets in oncology and immunology. For more information, please visit .

公司正在利用其专有的化学蛋白质组学平台，推进一系列针对高价值、传统上不可成药的肿瘤学和免疫学靶点的高度选择性小分子治疗药物的多样化管线。欲了解更多信息，请访问。

www.vividion.com

。

Find more information at

更多信息请访问

https://pharma.bayer.com

在Facebook上关注我们：

http://www.facebook.com/bayer

Forward-Looking Statements

前瞻性声明

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.

本发布可能包含基于拜耳管理层当前假设和预测的前瞻性声明。各种已知和未知的风险、不确定性和其他因素可能导致公司的实际未来结果、财务状况、发展或业绩与这里给出的估计值存在重大差异。

These factors include those discussed in Bayer’s public reports which are available on the Bayer website at .

这些因素包括拜耳公开报告中讨论的因素，这些报告可在拜耳网站上查阅。

www.bayer.com

. The company assumes no liability whatsoever to update these forward-looking statements or to conform

公司不承担更新这些前瞻性陈述或使其符合的任何责任。

them to future events or developments.

将它们应用于未来的事件或发展。

Kolluri A and Ho M (2019), The Role of Glypican-3 in Regulating Wnt, YAP, and Hedgehog in Liver Cancer.

Kolluri A 和 Ho M (2019)，甘露聚糖-3 在调控肝癌中 Wnt、YAP 和 Hedgehog 的作用。

Front. Oncol.

前沿. 肿瘤学